Search | Clinical Trials Finder

Conditions: Postsurgical Pain
Interventions: CA-008, Placebo; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 193 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 4
States / cities: Pasadena, California • Carrollton, Texas • Houston, Texas + 1 more

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: INGAP-Peptide, placebo; Drug
Lead sponsor: Exsulin Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 10
States / cities: Irvine, California • San Diego, California • Walnut Creek, California + 6 more

Conditions: Hepatorenal Syndrome, Acute Kidney Injury
Interventions: R2R01, Terlipressin; Drug
Lead sponsor: River 2 Renal Corp.; Industry
Eligibility: 18 Years and older
Enrollment: 95 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 7
States / cities: San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 4 more

Conditions: Infertility
Interventions: GnRH iontophoretic transdermal Lutrepatch, clomiphene citrate, placebo clomiphene citrate, placebo GnRH patch; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 38 Years · Female only
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 35
States / cities: Tucson, Arizona • Jonesboro, Arkansas • San Diego, California + 30 more

Conditions: Aging, Aging Well, Healthy Aging
Interventions: Nitrate enriched beetroot juice, Nitrate depleted beetroot juice, 12 week of combined exercise training; Dietary Supplement · Other
Lead sponsor: Florida Institute for Human and Machine Cognition; Other
Eligibility: 60 Years and older
Enrollment: 226 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Pensacola, Florida

Conditions: Hypertension
Interventions: clevidipine, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 12
States / cities: Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more

Conditions: Metabolic Syndrome X
Interventions: NOS Inhibition, ET-1 Inhibition, NOS Inhibition Placebo, 3 Tesla MRI, Intravenous Catheter, Oral Glucose Tolerance Test, ET-1 Inhibition Placebo; Drug · Device · Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Pseudoachondroplasia
Interventions: resveratrol, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Respiratory Distress Syndrome, Newborn, Premature Birth, Bronchopulmonary Dysplasia
Interventions: Lucinactant 175 mg/kg, Lucinactant 90 mg/kg, Placebo; Drug
Lead sponsor: Windtree Therapeutics; Industry
Eligibility: 3 Days to 10 Days
Enrollment: 136 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Warrington, Pennsylvania

Conditions: Drug Allergy, Cephalosporin Allergy, Drug Hypersensitivity, Antibiotic Allergy, Beta Lactam Adverse Reaction, Drug-Induced Anaphylaxis, Cephalosporin Reaction
Interventions: Beta-lactam antibiotic (cefazolin, cefuroxime, cefotaxime, ceftazidime, ceftriaxone, cefepime, pre-pen, penicillin G, ampicillin, and histamine) double-blind skin testing, Culprit cephalosporin (cefazolin, ceftazidime, ceftriaxone, cefepime, cephalexin, cefaclor, cefadroxil, cefuroxime, cefpodoxime, cefdinir, or cefixime) double-blind placebo-controlled drug challenge, Similar cephalosporin (cefepime, ceftriaxone, cefaclor, cephalexin, cefixime, or cefdinir) antibiotic double-blind placebo-controlled drug challenge, Dissimilar cephalosporin (ceftriaxone or cefazolin) antibiotic double-blind placebo-controlled drug challenge, Amoxicillin double-blind placebo-controlled drug challenge; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Scottsdale, Arizona • San Francisco, California • Boston, Massachusetts + 3 more

Conditions: Catheter Occlusion, Thrombosis
Interventions: CUSA-081, Placebo, Alteplase; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more

Conditions: Glycemia
Interventions: Berberine, Dihydroberberine 200, Dihydroberberine 100, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Type1diabetes, Hypoglycemia, Hypoglycemia Unawareness, Islet Cell Transplantation
Interventions: Phentolamine, Propranolol, Placebo; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 21 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postmenopausal Osteoporosis
Interventions: Romosozumab 90 mg/mL, Placebo 90 mg/mL, Romosozumab 70 mg/mL, Placebo 70 mg/mL; Drug
Lead sponsor: Amgen; Industry
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 294 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 2
States / cities: Gainesville, Georgia • Bethesda, Maryland

Conditions: Epilepsy
Interventions: Brivaracetam tablets, Brivaracetam bolus, Brivaracetam infusion, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Lexington, Kentucky + 5 more

Conditions: Familial Hypercholesterolemia - Homozygous
Interventions: Inclisiran, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Plaque Psoriasis
Interventions: Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 8
States / cities: Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more

Conditions: Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)
Interventions: ASP0113, Placebo; Biological · Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 514 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 22 more

Search by objective public record fields.

Study Evaluating the Safety, Efficacy and Pharmacokinetics of CA-008 (Vocacapsaicin)

Safety and Efficacy of INGAP-Peptide in Patients With Type 1 Diabetes

Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome

Study to Assess the Efficacy and Safety of Three Dosage Strengths of Pulsatile GnRH Delivered From a Iontophoretic Patch Compared to Oral Treatment With Clomiphene or Placebo in Infertile Females

Adjuvant Nitrate to Boost Exercise-induced Health Benefits in Older Adults

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

Mechanisms of Cerebrovascular Control

Resveratrol Trial for Relief of Pain in Pseudoachondroplasia

SURFAXIN® Treatment for Prevention of Bronchopulmonary Dysplasia (BPD) in Very Low Birth Weight (VLBW) Infants.

Optimizing the Diagnostic Approach to Cephalosporin Allergy Testing

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Bioavailability of Berberine and Dihydroberberine and Their Impact on Glycemia

Adrenergic System in Islet Transplantation

A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis

Safety and Tolerability of Intravenous Brivaracetam (Infusion or Bolus) as Adjunctive Antiepileptic Therapy

Study to Evaluate Efficacy and Safety of Inclisiran in Adolescents With Homozygous Familial Hypercholesterolemia

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)